FDA approves first subcutaneous drug for EGFR-mutated non-small cell lung cancer

The U.S. Food and Drug Administration has approved Rybrevant Faspro (amivantamab and hyaluronidase-lpuj) as the first and ...
Medscape

Sunvozertinib Wins Approval for EGFR-Mutated NSCLC

The FDA has granted accelerated approval to sunvozertinib (Zegfrovy, Dizal Pharmaceutical) for locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor ( ...
Medscape

New EGFR Lung Cancer Drug Nears EU Approval

The third generation EGFR TKI targets EGFR mutant NSCLC, showing improved progression free survival and fewer adverse events ...
Monthly Prescribing Reference

Datopotamab Deruxtecan Gets Priority Review For Advanced EGFR-Mutated NSCLC

The Prescription Drug User Fee Act target date has been set for the third quarter of 2025. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application ...
EurekAlert!

Netrin-1, a neural guidance protein, restricts hepatitis b virus infection

Researchers at the Kanazawa University Graduate School of Medical Sciences report in PLOS Pathogens a novel role for the ...
The Manila Times

Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC

The study is designed to evaluate the safety and clinical activity of NXP900 in combination with osimertinib in patients with epidermal growth factor receptor mutated (EGFR mut+) non-small cell lung c ...